This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN (QGEN), led by progress in the test menu expansion strategy.
QIAGEN (QGEN) Acquires the Forensics NGS Firm Verogen
by Zacks Equity Research
QIAGEN's (QGEN) acquisition of Verogen fortifies the company's position in the fast-growing field of Human ID and forensics.
QIAGEN's (QGEN) Therascreen KRAS Kit Receives FDA Approval
by Zacks Equity Research
QIAGEN's (QGEN) therascreen-based companion diagnostic detects KRAS G12C, a genetic mutation that is one of the most common KRAS variations related to cancer.
QIAGEN's (QGEN) New Monkeypox Test to Aid Faster Identification
by Zacks Equity Research
QIAGEN's (QGEN) latest multiplex test is expected to strengthen its portfolio and boost its fight against the global monkeypox outbreak.
3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on the back of a series of product launches.
QIAGEN's (QGEN) Q3 Earnings Top Estimates, 2022 View Up
by Zacks Equity Research
The ongoing double-digit sales growth in the non-COVID product portfolio, a high level of profitability and strong cash flow are the major upsides for QIAGEN (QGEN).
Qiagen (QGEN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 17.78% and 4.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Qiagen (QGEN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PacBio's (PACB) Latest Offering to Enhance Genome Sequencing
by Zacks Equity Research
PacBio's (PACB) latest sequencing panels are expected to simplify the study of the difficult-to-sequence or accurately map genomes, thereby aiding researchers.
PacBio's (PACB) Latest Offering to Enhance Disease Discoveries
by Zacks Equity Research
PacBio's (PACB) latest sequencing kit is expected to help generate insights into how single-cell research can power new disease discoveries and the identification of therapeutic targets across many categories.
BD's (BDX) Latest Monkeypox PCR Assay Commercially Available
by Zacks Equity Research
BD's (BDX) new molecular RUO PCR assay is expected to aid in better managing the ongoing global monkeypox outbreak.
Quest Diagnostics (DGX) & Peers Progress With Monkeypox Testing
by Zacks Equity Research
Quest Diagnostics in its latest media report notes that demand for COVID-19 molecular diagnostic testing declined in August compared to the prior month.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN's (QGEN) better-than-expected results and solid genomics uptake.
QIAGEN (QGEN) Assays to Detect Organ Transplant-Related Viruses
by Zacks Equity Research
QIAGEN's (QGEN) latest additions to the NeuMoDx assay menu will help identify EBV and HHV-6 viruses in immunocompromised patients.
QIAGEN (QGEN) to Develop Companion Diagnostic for Neuron23
by Zacks Equity Research
QIAGEN's (QGEN) novel companion diagnostic assay will help identify individuals who might benefit from Neuron23's drug candidate for Parkinson's disease.
QIAGEN's (QGEN) New Syndromic Test to Combat Monkeypox Spread
by Zacks Equity Research
QIAGEN (QGEN) joins the global fight against monkeypox with the launch of its novel QIAstat-Dx Viral Vesicular Panel RUO.
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
QIAGEN (QGEN) posts better-than-expected results for the second quarter and raises its sales and earnings outlook for 2022 amid the uncertain macroeconomic environment.
Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 13.33% and 3.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
QIAGEN (QGEN) QCI's Robust Adoption to Enhance Patient Outcome
by Zacks Equity Research
QIAGEN's (QGEN) QCI platform is expected to significantly streamline NGS data analysis and variant interpretation, and enable swift and confident shift by users from raw NGS data to clinical report.
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 2.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Novavax (NVAX) Down 11.7% Since Last Earnings Report?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Fate Therapeutics (FATE) Down 14.1% Since Last Earnings Report?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Qiagen (QGEN) Up 0.1% Since Last Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN (QGEN), owing to strong international growth and bullish guidance.
QIAGEN (QGEN) Unveils New Enhancements to QIAstat-Dx Portfolio
by Zacks Equity Research
The launch of QIAstat-Dx Rise and other advancements to the QIAstat-Dx portfolio are expected to strengthen QIAGEN's (QGEN) syndromic testing solutions.